A common variant near the FTO gene is linked to a small average increase in body weight and BMI by nudging appetite regulation. Most carriers never become obese — environment and behavior still matter most.
Obesity is shaped by hundreds of genes acting alongside diet, activity, sleep, medications, and the environment a person lives in. Of all the genes studied so far, the one most consistently and strongly linked to body weight in genome-wide studies is FTO ("fat mass and obesity-associated"), on chromosome 16. A specific marker within this gene, rs9930506, was one of the first common variants ever shown — in a 2007 study of thousands of Sardinian villagers — to nudge body mass index (BMI), weight, and hip circumference in a population.
It is important to say plainly, up front: this is a small effect. Carrying the version of this variant linked to higher weight does not mean a person is destined to develop obesity, and not carrying it is no guarantee of staying lean. Most people who carry the higher-weight-associated version of this variant never become obese, and many people without it do. This page is about a genuine, replicated, but modest statistical tendency — not a diagnosis and not a life sentence.
The FTO variant does not directly control fat storage or metabolism in any simple sense. The best evidence points to an effect on appetite regulation in the brain, particularly circuits in the hypothalamus that govern hunger and satiety signaling. People carrying the higher-weight-associated version of nearby FTO variants have, on average in study populations, reported somewhat reduced feelings of fullness after eating and a mild tendency toward higher food intake — small shifts that, compounded over years, translate into a modest average difference in body weight at the population level.
Separately, laboratory work has shown that variation in this same stretch of DNA can also affect nearby genes called IRX3 and IRX5, which influence whether developing fat cells become energy-storing ("white") fat or more metabolically active, heat-generating ("beige") fat. That mechanistic work focused on a different, nearby FTO-region SNP (rs1421085) that travels together with rs9930506 on the same stretch of inherited DNA in many people, so the two lines of evidence — brain appetite circuits and fat-cell biology — likely describe two contributing pieces of the same overall picture rather than competing explanations.
In the original 2007 Sardinian study, people who inherited two copies of the higher-weight-associated version of this specific marker had, on average, a BMI about 1.3 units higher than those with two copies of the other version — roughly the difference between, say, a BMI of 24 and a BMI of 25.3 for someone of average height. Follow-up studies in European-American and Hispanic-American populations found a similar, slightly smaller difference (roughly 1.0 BMI unit between the two extreme genotype groups). A large, closely related FTO marker studied separately found that adults who inherited two copies of its higher-weight-associated version weighed about 3 kilograms more on average, and had roughly 1.7 times higher odds of obesity, compared with people carrying no copies.
These are population averages spread across a bell curve, not individual predictions. A single common variant like this one explains only a sliver of the difference in body weight between any two people — genetics researchers estimate that all known common obesity-associated variants combined still leave most of the variation in body weight unexplained, with lifestyle, environment, and many other factors accounting for the rest.
It's worth distinguishing this common, modest-effect variant from the rare, much more disruptive gene changes that can cause severe childhood-onset obesity on their own — for example, mutations affecting the leptin or melanocortin (MC4R) appetite pathways. Those are uncommon and behave very differently in a family (often causing extreme early obesity along with other features). The FTO variant discussed here is the opposite kind of finding: extremely common, found in a large share of people across many populations, and individually weak — one contributor among hundreds of genetic and non-genetic factors rather than a determining cause.
Body weight is influenced by genetics, but genetics is not destiny, and no variant discussed here should be read as a verdict on anyone's body, willpower, or health. If anything, understanding that appetite regulation has a real biological, partly inherited basis can be reassuring — some people genuinely have to work harder against hunger signals than others, and that is a difference in physiology, not character. The same evidence base that identified this variant also consistently shows that diet quality, physical activity, sleep, and overall environment continue to shape body weight regardless of genotype, and several studies suggest that regular physical activity can blunt the size of FTO's effect on weight.
Locus and variant. rs9930506 is an intronic single-nucleotide variant within FTO (alpha-ketoglutarate-dependent dioxygenase FTO; OMIM *610966) at chromosome 16q12.2. It sits within the large first intron of FTO, a region now understood to function as a long-range regulatory element rather than to affect FTO's own enzymatic (RNA demethylase) activity directly.
Discovery and effect size. rs9930506 was identified as the lead FTO variant for body-weight traits in a genome-wide association scan of 4,741–6,148 Sardinian individuals (ages 14–102) from the Lanusei Valley (Scuteri et al., PLoS Genetics 2007; PMID 17658951; GWAS Catalog trait "Obesity-related traits," study GCST000060). It was the most significantly associated FTO SNP for BMI (p = 8.6×10⁻⁷), hip circumference (p = 3.4×10⁻⁸), and weight (p = 9.1×10⁻⁷) in that cohort. Homozygotes for the common allele versus the alternate allele (minor allele frequency ≈ 0.46 in Sardinians) differed by approximately 1.3 BMI units on average; the association replicated in independent GenNet cohorts of European-American (n=1,496) and Hispanic-American (n=839) ancestry with an approximately 1.0 BMI-unit difference between homozygote groups (combined replication p between 0.0005 and 0.001), but did not reach significance in an African-American sample, where the relevant allele frequency was lower (≈0.21) and local linkage disequilibrium patterns differ. A later multi-ancestry meta-analysis (Wojcik et al., Nature 2019; PMID 31217584), incorporating African-American, Hispanic/Latino, Asian, Native Hawaiian, and Native American ancestry cohorts, confirmed genome-wide-significant association of rs9930506 with BMI (β ≈ 0.06 BMI units per copy, 95% CI 0.048–0.076, p = 4×10⁻¹⁸ per GWAS Catalog).
Relationship to other FTO markers. rs9930506 is in strong linkage disequilibrium with rs9939609, the FTO marker used in the landmark Frayling et al. study (Science 2007; PMID 17434869), which found that the 16% of adults homozygous for its risk allele weighed about 3 kg more and had a 1.67-fold higher odds of obesity than non-carriers, with the effect detectable from age 7 onward and reflecting increased fat mass specifically rather than lean mass or height. Because these markers travel together on the same haplotype in much of the genome studied, effect-size figures reported for one closely approximate, but are not identical to, the other.
Proposed mechanism. Functional work by Claussnitzer et al. (NEJM 2015; PMID 26287746) traced a causal mechanism to a different but nearby FTO-intron variant, rs1421085, showing that its risk allele disrupts a repressor binding motif (ARID5B), de-represses a preadipocyte enhancer, and roughly doubles expression of two adjacent genes, IRX3 and IRX5, during early adipocyte differentiation. This shifts precursor cells away from thermogenic ("beige/brite") fat and toward energy-storing white fat, reducing mitochondrial thermogenesis roughly fivefold in cell models; CRISPR correction of rs1421085 restored thermogenic gene expression. Because rs9930506 lies in the same regulatory haplotype block, it is generally interpreted as a marker in linkage with this regulatory mechanism rather than a demonstrated causal variant in its own right; appetite/satiety effects mediated via hypothalamic FTO/FTM circuitry have also been proposed and are not mutually exclusive with the adipocyte mechanism.
Population variation and equity caveat. Effect-allele frequency for FTO obesity-associated variants differs substantially by ancestry (common in European, South Asian, and some African populations; generally lower average BMI effect reported in East Asian cohorts for some correlated markers), and most large discovery cohorts have been of European ancestry, so caution is warranted before generalizing point estimates across all populations.
Diagnostic context. Clinical obesity is defined by BMI thresholds (BMI ≥30 kg/m² in most adult clinical guidelines) or by direct adiposity measures, never by genotype; rs9930506 and related FTO markers are population risk-modifiers used in research and polygenic risk contexts, not diagnostic or predictive tests for any individual.
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about Obesity and the FTO Gene comes down to these specific, well-studied positions — not a diagnosis.
No. It is associated with only a small average shift in body weight — on the order of one BMI unit or a few kilograms when comparing large groups of people. Most people who carry the higher-weight-associated version never develop obesity, and many people without it do. It is a modest risk-modifier, not a diagnosis or a prediction for any one person.
It sits in a regulatory region of the FTO gene that has been linked to appetite and satiety signaling in the brain, and — through a nearby, closely linked variant — to whether developing fat cells favor energy storage or heat-generating metabolism. It does not appear to act through FTO's own enzyme function directly.
It's the most consistently replicated common obesity-associated gene found so far, but it is one of hundreds of genes with small effects on body weight, not a single dominant cause. Rare mutations in other genes (such as those in the leptin or MC4R appetite pathways) can cause severe obesity on their own, but those are uncommon and genetically distinct from this common variant.
The evidence base underlying this variant's discovery consistently shows that lifestyle factors continue to shape body weight regardless of genotype, and several studies suggest regular physical activity can blunt FTO's average effect on weight. Genetics loads the dice; it does not decide the outcome.
No. Its frequency and its measured effect size differ across ancestry groups, and most of the original discovery research was done in European and Sardinian populations. A 2019 multi-ancestry study confirmed the association in several other populations, but it was not statistically significant in an African-American sample, likely reflecting a lower allele frequency and different local genetic structure in that group.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.